Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients
Summary
- STRIIVING study demonstrated that switching from virologically suppressive regimen (2 NRTIs plus PI, NNRTI, or INSTI) to single-tablet, once-daily abacavir/dolutegravir/lamivudine was noninferior to continuing baseline ART for maintenance of virologic suppression at Week 24[Trottier 2017]
- NEAT-022 study showed that switching virologically suppressed patients with high cardiovascular risk from their current regimen to dolutegravir-based ART was noninferior and improved lipid profiles[Gatell 2017]
- French study assessed the efficacy and safety of switching virologically suppressed patients from a regimen of dolutegravir plus abacavir/lamivudine (either as separate components or as a coformulated regimen) to bictegravir/emtricitabine/tenofovir AF[Molina 2018]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Switch Strategies